Article
Effects of CYP3A4 and CYP2C9 genotype on systemic anastrozole and fulvestrant concentrations in SWOG S0226.
Pharmacogenomics - 1 Aug 2023
Rutherford Delaney V, Medley Sarah, Henderson Nicholas C, Gersch Christina L, Vandenberg Ted A, Albain Kathy S, Dakhil Shaker R, Tirumali Nagendra R, Gralow Julie R, Hortobagyi Gabriel N, Pusztai Lajos, Mehta Rita S, Hayes Daniel F, Kidwell Kelley M, Henry N Lynn, Barlow William E, Rae James M, Hertz Daniel L
Abstract excerpt
Objective & methods: This study tested associations of genotype-predicted activity of CYP3A4, other pharmacogenes, SLC28A7 (rs11648166) and ALPPL2 (rs28845026) with systemic concentrations of the endocrine therapies anastrozole and fulvestrant in SWOG S0226 trial participants. Results: Participants in the anastrozole-only arm with low CYP3A4 activity (i.e. CYP3A4*22 carriers) had higher systemic anastrozole...
Read the complete abstract on PubMed